GFAP and early-onset autosomal dominant Alzheimer disease: Given findings that glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, shows promise as a biomarker for traumatic brain injury (TBI) [6], Alzheimer disease [7] and other diseases, we examined the potential utility of GFAP as a biomarker for FTD.